ARS Pharmaceuticals (SPRY) Hisse Özeti
Bir biyofarmasötik şirketi olan ARS Pharmaceuticals, Inc. şiddetli alerjik reaksiyonlar için Amerika Birleşik Devletleri'nde ve uluslararası alanda tedaviler geliştirmekte ve ticarileştirmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 4/6 |
| Gelecekteki Büyüme | 5/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
Ödüller
Risk Analizi
Risk kontrollerimizden SPRY için herhangi bir risk tespit edilmedi.
SPRY Community Fair Values
Create NarrativeSee what 50 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
ARS Pharmaceuticals, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$8.60 |
| 52 Haftanın En Yüksek Seviyesi | US$18.90 |
| 52 Haftanın En Düşük Seviyesi | US$6.66 |
| Beta | 0.80 |
| 1 Aylık Değişim | 6.83% |
| 3 Aylık Değişim | -13.31% |
| 1 Yıllık Değişim | -35.29% |
| 3 Yıllık Değişim | 10.12% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | 41.91% |
Son Haberler & Güncellemeler
Analiz Güncellemesi • May 01
SPRY: Disruptor Positioning And Recent Approvals Will Support Future Upside Potential
Analysts have adjusted their price target for ARS Pharmaceuticals slightly from about $27.00 to roughly $26.71. This reflects updated assumptions around discount rates, profit margins, revenue growth, and future P/E expectations following recent bullish Street research initiations.
Analiz Güncellemesi • Apr 15
SPRY: Bullish Coverage Sees Future Upside From Execution On Commercial Rollout
Analysts have reset their fair value estimate for ARS Pharmaceuticals to $34.00 from $40.00, reflecting updated assumptions on revenue growth, profit margins, discount rate, and future P/E following recent bullish coverage initiations. Analyst Commentary Recent bullish coverage initiations frame ARS Pharmaceuticals as a potential disruptor in its category, with valuation work now anchored to the revised US$34.00 fair value estimate.
Analiz Güncellemesi • Apr 01
SPRY: Rival FDA Setback Will Support Future Anaphylaxis Market Upside
Narrative Update: ARS Pharmaceuticals (SPRY) Analysts have nudged their fair value estimate for ARS Pharmaceuticals slightly higher to about $12.08 per share, citing updated assumptions on revenue growth, profit margins and future P/E multiples following a recent research note highlighting regulatory setbacks for a key competitor. Analyst Commentary Recent research has framed the regulatory setback at a key competitor as a potential opening for ARS Pharmaceuticals, but bearish analysts still flag important risks around execution and valuation.Recent updates
Analiz Güncellemesi • May 01
SPRY: Disruptor Positioning And Recent Approvals Will Support Future Upside Potential
Analysts have adjusted their price target for ARS Pharmaceuticals slightly from about $27.00 to roughly $26.71. This reflects updated assumptions around discount rates, profit margins, revenue growth, and future P/E expectations following recent bullish Street research initiations.Analiz Güncellemesi • Apr 15
SPRY: Bullish Coverage Sees Future Upside From Execution On Commercial Rollout
Analysts have reset their fair value estimate for ARS Pharmaceuticals to $34.00 from $40.00, reflecting updated assumptions on revenue growth, profit margins, discount rate, and future P/E following recent bullish coverage initiations. Analyst Commentary Recent bullish coverage initiations frame ARS Pharmaceuticals as a potential disruptor in its category, with valuation work now anchored to the revised US$34.00 fair value estimate.Analiz Güncellemesi • Apr 01
SPRY: Rival FDA Setback Will Support Future Anaphylaxis Market Upside
Narrative Update: ARS Pharmaceuticals (SPRY) Analysts have nudged their fair value estimate for ARS Pharmaceuticals slightly higher to about $12.08 per share, citing updated assumptions on revenue growth, profit margins and future P/E multiples following a recent research note highlighting regulatory setbacks for a key competitor. Analyst Commentary Recent research has framed the regulatory setback at a key competitor as a potential opening for ARS Pharmaceuticals, but bearish analysts still flag important risks around execution and valuation.Analiz Güncellemesi • Mar 18
SPRY: Competitor FDA Setback Will Support Future Upside Potential
Analysts now set a revised price target of about $27 for ARS Pharmaceuticals, down from roughly $28.83. This reflects updated assumptions around higher projected revenue growth, a lower profit margin profile, and a higher future P/E, with recent competitor regulatory setbacks cited as an important supporting factor.Analiz Güncellemesi • Mar 04
SPRY: Rival FDA Setback And Global Approvals Will Support Future Upside
Narrative Update on ARS Pharmaceuticals (SPRY) Analysts have lifted their price target on ARS Pharmaceuticals to $12.00, citing updated assumptions around discount rate, revenue growth, profit margin, and future P/E that, in their view, reflect a more favorable competitive setup following a deficiency letter issued to a key rival by the FDA. Analyst Commentary Even with a raised price target to US$12.00 tied to a tougher outlook for a key rival, analysts are not uniformly enthusiastic.Analiz Güncellemesi • Feb 18
SPRY: Competitor FDA Setback And Global Approvals Will Support Future Upside
Analysts now see fair value for ARS Pharmaceuticals rising slightly from about $28.00 to roughly $28.83 per share, citing the recent FDA deficiency letter to a key competitor as support for their updated price target and underlying assumptions. Analyst Commentary Bullish Takeaways Bullish analysts view the FDA deficiency letter to a key competitor as easing near term competitive pressure on ARS Pharmaceuticals, which they see as supportive of the updated fair value near US$28.83 per share.Seeking Alpha • Feb 14
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
Summary SPRY’s main product is Neffy, which is a needle-free epinephrine spray. Its sales are ramping quickly, and Q3 2025 sales hit $31.3 million. My core thesis is that Neffy’s more convenient delivery mechanism will resonate with patients far better than injections. Also, a convenient nasal spray is a much simpler administration method that should reduce user error and unlock diagnosed-but-untreated anaphylaxis demographics. SPRY also has international approvals and partners (Europe, UK, Japan, China, Australia), which help diversify its commercialization risk beyond the US. In my view, CSU (currently in Phase 2b) could open another valuable franchise as well. So, on balance, I feel SPRY now offers a compelling “Buy” opportunity. Read the full article on Seeking AlphaAnaliz Güncellemesi • Feb 03
SPRY: Competitor Delay And Global Allergy Access Will Drive Future Upside
Narrative Update on ARS Pharmaceuticals Analysts trimmed their fair value estimate for ARS Pharmaceuticals from about $28.83 to $28.00, reflecting slightly adjusted assumptions around discount rates, revenue growth, profit margins, and future P/E. They also highlighted competitor delays and recent strength in Neffy uptake and revenue as key parts of their rationale.Analiz Güncellemesi • Jan 19
SPRY: Virtual Access And China Approval Will Drive Needle Free Allergy Share
Analysts have reduced their price targets on ARS Pharmaceuticals to a range centered around roughly US$30 to US$35, citing ongoing momentum for neffy, recent revenue outperformance, and a potentially delayed competitive launch following the FDA deficiency letter to a rival product. Analyst Commentary Recent research updates on ARS Pharmaceuticals focus heavily on neffy adoption, revenue traction, and the competitive backdrop in anaphylaxis treatment.Analiz Makalesi • Jan 10
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) shareholders would be excited to see that the share price has had a great...Analiz Güncellemesi • Jan 05
SPRY: Needle Free Allergy Rescue Will Gain Share On Virtual Access Programs
Analysts have inched their fair value estimate for ARS Pharmaceuticals higher to about $28.83 per share from roughly $28.67, citing strong recent revenue from Neffy, fresh Street targets in the $30 to $35 range, and expectations for continued adoption supported by direct to consumer efforts and broader prescriber uptake. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the recent Q3 revenue of $32.5M exceeded both Street consensus and internal models.Analiz Güncellemesi • Dec 15
SPRY: Neffy Launch Momentum And DTC Campaigns Will Drive Future Upside
Analysts have revised their price target on ARS Pharmaceuticals lower, effectively halving fair value to about $12 per share from roughly $25, as they balance stronger than expected Neffy launch metrics and accelerating revenue growth with a higher discount rate and more conservative long term valuation multiples. Analyst Commentary Recent Street research continues to frame ARS Pharmaceuticals as a high growth story supported by strong Neffy uptake, but with a more tempered risk reward profile as valuation, competitive dynamics, and launch execution risks are reassessed.Analiz Güncellemesi • Nov 30
SPRY: Needle-Free Delivery Will Capture Market Share From Auto-Injectors
The analyst fair value estimate for ARS Pharmaceuticals has been lowered from approximately $30.00 to $28.67 per share. Analysts cite moderating revenue growth expectations and a significant reduction in projected profit margins as key factors driving the adjustment, despite continued positive momentum for the company's signature product, neffy.Analiz Güncellemesi • Nov 16
SPRY: Needle-Free Allergy Treatment Will Drive Market Share Expansion
The analyst price target for ARS Pharmaceuticals has been lowered from $31.00 to $30.00 per share, as analysts cite strong recent financials, expanding market share for Neffy, and optimism about future adoption. This outlook is balanced by moderated revenue growth expectations.Analiz Makalesi • Aug 28
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) shares have had a horrible month, losing 27% after a relatively good period...Analiz Makalesi • Aug 15
ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
NasdaqGM:SPRY 1 Year Share Price vs Fair Value Explore ARS Pharmaceuticals's Fair Values from the Community and select...Analiz Makalesi • Jun 30
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) shares have been powering on, with a gain of...Analiz Makalesi • May 15
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%
Today is shaping up negative for ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) shareholders, with the analysts delivering a...
Yeni Analiz • May 01
80% Coverage And Pediatric Launch Will Expand Global Markets
Rapid payer coverage expansion and pediatric market entry may enhance revenue and ease prescribing burdens with reduced authorization requirements.Analiz Makalesi • Apr 03
Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%
ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) shareholders would be excited to see that the share price has had a great...Analiz Makalesi • Mar 26
Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term
One thing we could say about the analysts on ARS Pharmaceuticals, Inc. ( NASDAQ:SPRY ) - they aren't optimistic, having...Seeking Alpha • Feb 06
ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
Summary ARS Pharmaceuticals launched Neffy, the first FDA-approved needle-free epinephrine nasal spray for severe allergic reactions. Neffy’s early sales also beat expectations, which I think showcases how much of a blockbuster it could become over time. Neffy targets several segments within severe allergic reactions and could also become an OTC medication soon. In total, this is a multibillion-dollar TAM. SPRY plans to expand Neffy’s indications into CSU and pediatric use relatively soon as well, which could give us further stock price catalysts in the near term. Still, there are a few risks related to insurance coverage policies and competition with traditional auto-injectors. But aside from that, I think SPRY is a 'Buy'. Read the full article on Seeking AlphaSeeking Alpha • Nov 20
ARS Pharmaceuticals: Demand Curve Is Key Unknown
Summary ARS Pharmaceuticals' Neffy, a first non-injectable epinephrine nasal spray, recently launched in the U.S. and Europe, helping to drive a 140% YTD stock increase. The company has a solid balance sheet with $205 million in cash and a new $145 million upfront payment as part of a licensing deal with ALK-Abelló. However, it is tough to determine the demand curve this close to the start of commercialization, and there has been some notable insider selling in November. An analysis around ARS Pharmaceuticals follows in the paragraphs below. Read the full article on Seeking AlphaAnaliz Makalesi • Sep 13
We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 06
ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Summary ARS Pharmaceuticals' neffy, a needle-free nasal spray for Type I allergic reactions, received early FDA approval, driving a 120% YTD share price increase. Neffy addresses a significant unmet need, potentially capturing a large market share from injectable epinephrine products like EpiPen, with projected peak revenues of ~$750m annually. Despite initial FDA rejection, neffy's approval is backed by compelling clinical data, and ARS plans to expand into Europe, China, Japan, and Australia. While ARS faces challenges from established competitors, neffy's advantages and ARS's strategic marketing efforts make it a slightly risky but compelling buy opportunity. Read the full article on Seeking AlphaSeeking Alpha • Jun 25
ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Summary ARS Pharmaceuticals stock has recovered since the FDA's Complete Response Letter regarding its epinephrine nasal spray, neffy. Despite competition and a delayed market entry, ARS Pharmaceuticals remains ahead with its unique nasal spray, aiming for a significant market share. With substantial cash reserves, ARS is financially stable until 2029, though increased expenses are anticipated as the product launch nears. SPRY stock is a hold, suited for a barbell strategy portfolio, balancing high risk/reward potential amidst significant competitive and regulatory risks. Read the full article on Seeking AlphaAnaliz Makalesi • Mar 18
We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analiz Makalesi • Nov 14
ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Analiz Makalesi • May 12
Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Hissedar Getirileri
| SPRY | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -2.6% | 0.1% | 2.6% |
| 1Y | -35.3% | 35.5% | 26.2% |
Getiri vs. Endüstri: SPRY geçen yıl % 35.5 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.
Getiri vs Piyasa: SPRY geçen yıl % 26.2 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| SPRY volatility | |
|---|---|
| SPRY Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: SPRY son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: SPRY 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2015 | 161 | Rich Lowenthal | ars-pharma.com |
Bir biyofarmasötik şirketi olan ARS Pharmaceuticals, Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda şiddetli alerjik reaksiyonlar için tedaviler geliştirmekte ve ticarileştirmektedir. Şirket, anafilaksi de dahil olmak üzere Tip I alerjik reaksiyonların acil tedavisi için iğnesiz intranazal epinefrin iletimi olan neffy'nin geliştirilmesinde yer almaktadır. ARS Pharmaceuticals, Inc. 2015 yılında kurulmuştur ve merkezi San Diego, Kaliforniya'da bulunmaktadır.
ARS Pharmaceuticals, Inc. Temel Bilgiler Özeti
| SPRY temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$867.89m |
| Kazançlar(TTM) | -US$171.30m |
| Gelir(TTM) | US$84.28m |
10.1x
P/S Oranı-5.0x
F/K OranıSPRY aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| SPRY gelir tablosu (TTM) | |
|---|---|
| Gelir | US$84.28m |
| Gelir Maliyeti | US$33.60m |
| Brüt Kâr | US$50.67m |
| Diğer Giderler | US$221.97m |
| Kazançlar | -US$171.30m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
May 16, 2026
| Hisse başına kazanç (EPS) | -1.73 |
| Brüt Marj | 60.13% |
| Net Kâr Marjı | -203.25% |
| Borç/Özkaynak Oranı | 147.5% |
SPRY uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/11 21:52 |
| Gün Sonu Hisse Fiyatı | 2026/05/11 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
ARS Pharmaceuticals, Inc. 11 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Carl Byrnes | Northland Capital Markets |